BeiGene USA, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$26.0M
Doctors Paid
8,503
Transactions
35,171
2024 Total
$13.4M
Payment Breakdown by Category
Research$16.1M (61.7%)
Consulting$2.2M (8.5%)
Food & Beverage$1.0M (3.9%)
Travel$650,960 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.1M | 1,524 | 61.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.4M | 1,750 | 20.9% |
| Consulting Fee | $2.2M | 1,280 | 8.5% |
| Food and Beverage | $1.0M | 28,714 | 3.9% |
| Travel and Lodging | $650,960 | 1,634 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $345,000 | 45 | 1.3% |
| Grant | $299,800 | 2 | 1.2% |
| Education | $5,855 | 222 | 0.0% |
Payments by Type
Research
$16.1M
1,524 transactions
General
$10.0M
33,647 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 1, Open-label, Randomized, Crossover Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Food on the Pharmacokinetics of a Single Oral Dose of BGB-43395 in Healthy Subjects | $1.9M | 0 | 12 |
| (BOVEN) Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). | $1.7M | 0 | 4 |
| BOVE ISR-CL-BGB3111-0005 | $1.3M | 0 | 4 |
| A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies | $953,275 | 0 | 4 |
| A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors | $923,690 | 0 | 509 |
| Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | $825,111 | 0 | 2 |
| A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B Cell Malignancies | $746,827 | 0 | 34 |
| A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Combination Therapy in Patients with Metastatic HR+/HER2- Breast Cancer and other Advanced Solid Tumors | $724,280 | 0 | 23 |
| A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors | $697,534 | 0 | 286 |
| BOVEN: Phase 2 study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Lymphoma (SLL) | $652,000 | 0 | 1 |
| Real World Treatment Patterns and Outcomes in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patinets Receiving Bruton Tyrosine Kinase Inhibitors (BTKi) | $565,904 | 0 | 1 |
| A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | $480,445 | 0 | 106 |
| A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | $452,238 | 0 | 9 |
| Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer | $279,441 | 0 | 76 |
| Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | $276,981 | 0 | 72 |
| A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors | $269,780 | 0 | 14 |
| A Phase 3 Randomized, Open-Label Study of Zanubrutinib (BGB-3111) Plus Rituximab Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma | $251,237 | 0 | 107 |
| An Open-Label, Multicenter, Single-Arm, Sequential Phase-2 Study of Mosunetuzumab Alone or With Zanubrutinib for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy | $230,766 | 0 | 1 |
| A Phase 2 Study with A Safety Lead-In of the Anti-Cd19 Antibody Tafasitamab with the BTK InhibitorZanubrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Taza CLL Study | $224,962 | 0 | 2 |
| A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenstrom Macroglobulinemia | $221,981 | 0 | 63 |
| A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | $203,807 | 0 | 12 |
| A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors | $157,755 | 0 | 2 |
| A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib | $144,809 | 0 | 9 |
| A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | $140,082 | 0 | 12 |
| A Phase 2 Open-Label, Multicenter Study of Rituximab and Zanubrutinib in Patients with indolent B-cell Lymphomas | $129,387 | 0 | 1 |
| A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy | $127,487 | 0 | 48 |
| retrospective review of outcomes in patients receiving oral specialty therapy for the treatment of chronic lymphocytic leukemia | $124,509 | 0 | 3 |
| A Single-dose, Open-label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of a Zanubrutinib 160 mg Tablet Compared to Two BRUKINSA (zanubrutinib) 80 mg Capsules | $118,056 | 0 | 4 |
| A Single-Dose, Open-Label, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of a Zanubrutinib 160 mg Tablet Compared to two 80 mg Capsules and to Evaluate the Effects of Food on the Pharmacokinetics of the Zanub | $117,448 | 0 | 4 |
| A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) | $113,991 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Moshe Levy, Md, MD | Medical Oncology | Dallas, TX | $292,235 | $0 |
| Kasra Karamlou, M.d, M.D | Hematology & Oncology | Sandusky, OH | $209,221 | $0 |
| Imad Tabbara, M.d, M.D | Hematology & Oncology | Washington, DC | $206,337 | $0 |
| John Allan, M.d, M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $184,054 | $0 |
| Andrew Whiteley | Internal Medicine | Dallas, TX | $171,503 | $0 |
| Ryan Jacobs, Md, MD | Internal Medicine | Charlotte, NC | $169,652 | $0 |
| Dr. Delong Liu, M.d., Ph.d, M.D., PH.D | Hematology | Hawthorne, NY | $165,117 | $0 |
| Hakan Kaya, M.d, M.D | Medical Oncology | Spokane, WA | $161,833 | $0 |
| Dr. Catherine Coombs, M.d, M.D | Hematology & Oncology | Orange, CA | $157,786 | $0 |
| Mohamed Hegazi, Md, MD | Internal Medicine | Louisville, KY | $152,879 | $0 |
| Dr. Habte Yimer, M.d, M.D | Hematology | Tyler, TX | $139,615 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $139,465 | $0 |
| Dr. Lori Leslie, M.d, M.D | Hematology | Hackensack, NJ | $133,806 | $0 |
| Dr. John Renshaw, M.d, M.D | Hematology & Oncology | San Antonio, TX | $128,529 | $0 |
| Javier Pinilla-Ibarz, Md, MD | Internal Medicine | Tampa, FL | $121,471 | $0 |
| Mohit Narang, M.d, M.D | Specialist | Owing Mills, MD | $111,361 | $0 |
| Cyrus Khan, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $102,004 | $0 |
| Dr. Daniel Efiom-Ekaha, Md, MD | Hematology & Oncology | York, PA | $100,878 | $0 |
| Dr. Anthony Nguyen, Md, MD | Hematology & Oncology | Henderson, NV | $100,386 | $0 |
| Jeffrey Schriber, M.d, M.D | Hematology & Oncology | Scottsdale, AZ | $91,505 | $0 |
| Yogesh Jethava, Md, MD | Hematology | Park Ridge, IL | $87,130 | $0 |
| Dr. Sayed Mehdi Hamadani, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $84,142 | $0 |
| Bachar Dergham, Md, MD | Hematology & Oncology | Cleveland, OH | $83,762 | $0 |
| Ahmed Galal, Md, MD | Hematology | Cincinnati, OH | $83,348 | $0 |
| Richard Mcdonough, M.d, M.D | Hematology & Oncology | Zephyrhills, FL | $79,842 | $0 |
Ad
Top Products
- BRUKINSA $14.7M
- TEVIMBRA $807,822
Payment Categories
- Food & Beverage $1.0M
- Consulting $2.2M
- Travel & Lodging $650,960
- Research $16.1M
About BeiGene USA, Inc.
BeiGene USA, Inc. has made $26.0M in payments to 8,503 healthcare providers, recorded across 35,171 transactions in the CMS Open Payments database. In 2024, the company paid $13.4M. The top product by payment volume is BRUKINSA ($14.7M).
Payments were distributed across 114 medical specialties. The top specialty by payment amount is Hematology & Oncology ($3.9M to 2,454 doctors).
Payment categories include: Food & Beverage ($1.0M), Consulting ($2.2M), Research ($16.1M), Travel & Lodging ($650,960).